8FJZ image
Entry Detail
PDB ID:
8FJZ
Title:
Crystal structure of HPK1 kinase domain T165E,S171E phosphomimetic mutant in complex with 3-{4-[(3R,5S)-3-Amino-5-methylpiperidin-1-yl]-6-chloro-7H-pyrrolo[2,3-d]pyrimidin-5-yl}benzonitrile
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2022-12-20
Release Date:
2023-04-05
Method Details:
Experimental Method:
Resolution:
1.90 Å
R-Value Free:
0.24
R-Value Work:
0.21
R-Value Observed:
0.21
Space Group:
P 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Mitogen-activated protein kinase kinase kinase kinase 1
Mutations:T165E, S171E
Chain IDs:A, B, C, D, E, F
Chain Length:331
Number of Molecules:6
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation

Abstact

Immune activating agents represent a valuable class of therapeutics for the treatment of cancer. An area of active research is expanding the types of these therapeutics that are available to patients via targeting new biological mechanisms. Hematopoietic progenitor kinase 1 (HPK1) is a negative regulator of immune signaling and a target of high interest for the treatment of cancer. Herein, we present the discovery and optimization of novel amino-6-aryl pyrrolopyrimidine inhibitors of HPK1 starting from hits identified via virtual screening. Key components of this discovery effort were structure-based drug design aided by analyses of normalized B-factors and optimization of lipophilic efficiency.

Legend

Protein

Chemical

Disease

Primary Citation of related structures